Giulia Barsotti

LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO

Chiara Cremolini, Daniele Rossini, Carlotta Antoniotti et al. · Annals of Oncology · 2021 · 32 citations

Medicine, Oncology, Pharmacotherapy +11

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study

Floriana Nappo, Lorenzo Fornaro, Luca Pompella et al. · Journal of Cancer Research and Clinical Oncology · 2023 · 25 citations · Full text

Medicine, Oncology, Perioperative Medicine +16

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

Letizia Procaccio, Valeria Merz, Morena Fasano et al. · Cancer Medicine · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini et al. · European Journal of Cancer · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study

Letizia Procaccio, Francesca Bergamo, Francesca Daniel et al. · Cancers · 2021 · 14 citations · Full text

Medicine, Clinical Sciences, Oncology +17